Research
Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces significantly greater reductions in HbA1c and body weight compared to semaglutide 1 mg and basal insulins in adults with type 2 diabetes.
Tirzepatide is a once-weekly injection that significantly lowers blood sugar and promotes substantial weight loss in people with type 2 diabetes, outperforming other common treatments like semaglutide and basal insulins in clinical trials.
StrongSupportsHIGH confidence
In SUPRASS-2, these reductions were greater than with the GLP-1 receptor agonist semaglutide 1 mg... Tirzepatide was associated with marked reductions of glycated haemoglobin (-1.87 to -2.59%) and body weight (-6.2 to -12.9 kg).
Why this rating
Phase 3 randomized controlled trials (SURPASS 1-5).
Source
Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective
Christophe De Block et al. · Diabetes Obesity and Metabolism · 2022
narrative_review · n=6263Cited 108×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →